Prostate cancer is lethal when tumors evolve to activate androgen receptor signaling, which circumvents ligand-deprivation therapy. In this issue of Cancer Cell, Groner et al. show that histone reader and transcription co-regulator TRIM24 occupies a central role in this evolution, nominating inhibitors of TRIM24’s bromodomain as a new therapeutic avenue.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Jun 13 2016|
ASJC Scopus subject areas
- Cell Biology
- Cancer Research